A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Epistemonikos ID: fcb1ffb08f86f8cbba03667287e15abef84edc1e
First added on: Feb 19, 2024